Cargando…

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

Several cancers are highly refractory to conventional chemotherapy. The survival of tumors in several cases is assisted by checkpoint immunomodulation to maintain the imbalance between immune surveillance and cancer cell proliferation. Check point antibody inhibitors, such as anti-PD-1/PD-L1, are a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alsaab, Hashem O., Sau, Samaresh, Alzhrani, Rami, Tatiparti, Katyayani, Bhise, Ketki, Kashaw, Sushil K., Iyer, Arun K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572324/ https://www.ncbi.nlm.nih.gov/pubmed/28878676 http://dx.doi.org/10.3389/fphar.2017.00561

Ejemplares similares

siRNA Delivery Strategies: A Comprehensive Review of Recent Developments
por: Tatiparti, Katyayani, et al.
Publicado: (2017)

Nano‐therapeutic strategies to target coronavirus
por: Rauf, Mohd Ahmar, et al.
Publicado: (2021)

PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer
por: Sau, Samaresh, et al.
Publicado: (2019)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Copper-Free ‘Click’ Chemistry-Based Synthesis and Characterization of Carbonic Anhydrase-IX Anchored Albumin-Paclitaxel Nanoparticles for Targeting Tumor Hypoxia
por: Tatiparti, Katyayani, et al.
Publicado: (2018)

Carbonic Anhydrase-IX Guided Albumin Nanoparticles for Hypoxia-mediated Triple-Negative Breast Cancer Cell Killing and Imaging of Patient-derived Tumor
por: Tatiparti, Katyayani, et al.
Publicado: (2020)

Folate Decorated Nanomicelles Loaded with a Potent Curcumin Analogue for Targeting Retinoblastoma
por: Alsaab, Hashem, et al.
Publicado: (2017)

Combination of Vancomycin and Cefazolin Lipid Nanoparticles for Overcoming Antibiotic Resistance of MRSA
por: Bhise, Ketki, et al.
Publicado: (2018)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
por: Wang, Mengjie, et al.
Publicado: (2022)

CD44 Targeted Nanomaterials for Treatment of Triple-Negative Breast Cancer
por: Nabil, Ghazal, et al.
Publicado: (2021)

Folate Receptors’ Expression in Gliomas May Possess Potential Nanoparticle-Based Drug Delivery Opportunities
por: McCord, Eva, et al.
Publicado: (2021)

Transferrin: Biology and Use in Receptor-Targeted Nanotherapy of Gliomas
por: Koneru, Tejaswi, et al.
Publicado: (2021)

Progress in Clinical Trials of Photodynamic Therapy for Solid Tumors and the Role of Nanomedicine
por: Alsaab, Hashem O., et al.
Publicado: (2020)

Development of asialoglycoprotein receptor directed nanoparticles for selective delivery of curcumin derivative to hepatocellular carcinoma
por: Yousef, Shaimaa, et al.
Publicado: (2018)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
por: Chocarro de Erauso, Luisa, et al.
Publicado: (2020)

Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes
por: Zheng, Dan, et al.
Publicado: (2022)

2391. Liposomal Vancomycin and Cefazolin Combinations for S. aureus Biofilms
por: Kebriaei, Razieh, et al.
Publicado: (2018)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

Controlling Nutritional Status (CONUT) Predicts Survival in Gastric Cancer Patients With Immune Checkpoint Inhibitor (PD-1/PD-L1) Outcomes
por: Chen, Li, et al.
Publicado: (2022)

Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study
por: Sun, Yiting, et al.
Publicado: (2021)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Corrigendum: Controlling nutritional status (CONUT) predicts survival in gastric cancer patients with immune checkpoint inhibitor (PD-1/PD-L1) outcomes
por: Chen, Li, et al.
Publicado: (2022)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
por: Gu, Tingxuan, et al.
Publicado: (2023)

Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
por: Anand, Kartik, et al.
Publicado: (2020)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
por: Zhang, Ke, et al.
Publicado: (2022)

Immunotherapy of alveolar echinococcosis via PD‐1/PD‐L1 immune checkpoint blockade in mice
por: Wang, Junhua, et al.
Publicado: (2018)

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
por: Zhang, Jian-ye, et al.
Publicado: (2020)

Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases
por: Singh, Vishakha, et al.
Publicado: (2021)

Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives
por: Zhao, Yating, et al.
Publicado: (2021)

Significant metabolic alterations in non-small cell lung cancer patients by epidermal growth factor receptor-targeted therapy and PD-1/PD-L1 immunotherapy
por: Yan, Chen, et al.
Publicado: (2022)

Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis
por: Xiang, Ze, et al.
Publicado: (2022)

Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers
por: Ou, Shun-Long, et al.
Publicado: (2023)

Abscopal Effects in Radio-Immunotherapy—Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition
por: Trommer, Maike, et al.
Publicado: (2019)

Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?
por: Feng, Yuqian, et al.
Publicado: (2021)

Corrigendum: Abscopal Effects in Radio-Immunotherapy—Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition
por: Trommer, Maike, et al.
Publicado: (2020)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
por: Broos, Katrijn, et al.
Publicado: (2018)

Editorial: Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies
por: Wang, Yiting, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q25uuvor8beimdief2bbo0dohl